Summary
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
Alkermes plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 107 | $3,308.11 | $5,583.79 | $2,275.68 | 68.79% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $2,798 | $5,218.5 | $2,420.5 | 86.51% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 5 | $139.9 | $260.9 | $121 | 86.49% |
 Farallon Capital Farallon Capital Management LLC | 20,800 | $686,816 | $1.09M | $400,088 | 58.25% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 742 | $25,088.45 | $38,762.08 | $13,673.63 | 54.5% |
Alkermes plc Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Paul Matteis Stifel | 210.08 | $10,865.32 | $11,111.11 | $245.79 | 2.26% |
Alkermes plc (ALKS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alkermes plc ever had a stock split?
Alkermes plc Profile
| Biotechnology Industry | Healthcare Sector | Richard F. Pops CEO | NASDAQ (NGS) Exchange | G01767105 CUSIP |
| IE Country | 2,050 Employees | - Last Dividend | 15 May 2000 Last Split | 16 Jul 1991 IPO Date |
Overview
Alkermes plc stands out as a pivotal player in the biopharmaceutical sector, dedicated to discovering, developing, and commercializing innovative pharmaceutical solutions aimed at fulfilling the unmet medical necessities of patients. The company's operations span across the United States, Ireland, and other global territories, focusing on significant therapeutic areas. Founded in 1987, with its headquarters located in Dublin, Ireland, Alkermes plc has carved a niche for itself by concentrating on the treatment of alcohol and opioid dependencies, schizophrenia, and bipolar I disorder. Through its dynamic portfolio of proprietary commercial products and a robust pipeline of clinical and preclinical candidates, Alkermes plc endeavors to transform the therapeutic landscape of neurological disorders. Moreover, the company fosters strategic collaboration agreements with prestigious entities such as Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International, leveraging its proprietary technology platforms to assist third parties in developing, commercializing, and manufacturing their products.
Products and Services
- ARISTADA: An innovative intramuscular injectable suspension, ARISTADA is meticulously designed for the treatment of schizophrenia. It represents a cornerstone in Alkermes plc’s portfolio, offering sustained relief and management of symptoms associated with this complex mental health condition.
- ARISTADA INITIO: Tailored for adults diagnosed with schizophrenia, ARISTADA INITIO embodies an enhanced treatment solution to initiate and stabilize patients. This formulation underscores Alkermes plc's commitment to advancing psychiatric care and improving patient outcomes through targeted therapy.
- VIVITROL: Manifesting a pioneering approach to overcoming alcohol and opioid dependence, VIVITROL is an extended-release, injectable medication. Its mechanism of action provides a non-addictive treatment pathway, significantly contributing to the prevention of relapse in individuals striving for recovery.
- LYBALVI: Emerging as a groundbreaking oral atypical antipsychotic candidate, LYBALVI is intended for the treatment of adults suffering from schizophrenia and bipolar I disorder. This promising product candidate exemplifies Alkermes plc’s relentless drive towards introducing novel therapies that encapsulate both safety and efficacy.
